Disolina is a medication indicated for the relief of the signs and symptoms of several inflammatory conditions.

• Management of mild to moderate pain and swelling associated with osteoarthritis (a condition affecting the joints), rheumatoid arthritis (a chronic condition causing joint discomfort), and ankylosing spondylitis (a form of arthritis that primarily affects the spine).
• Is used for the acute treatment of migraine attacks with or without aura in adult patients. It may provide relief when a migraine has already begun.
• Can contribute to the management of mild to moderate acute pain from various sources.

Treatment with Disolina helps manage the discomfort associated with these conditions. It is important to note that it is typically used as part of a total treatment plan that may support overall patient comfort.

Who can and cannot use Disolina?

The population eligibility for Disolina is determined by specific regulatory exclusions and limitations documented in official labeling, primarily restricting use based on hypersensitivity, age, and reproductive status.

---

Absolute Contraindications

Classification	Rule
Contraindicated	Patients with known hypersensitivity or allergy to the active ingredients (Diosmin, Hesperidin, or Micronized Purified Flavonoid Fraction) or any other component [2.3].

---

Restricted and Non-Eligible Populations

Population Group	Eligibility Status
Pediatric Patients	Not recommended in children and adolescents under 18 years of age; safety and efficacy have not been established [1.1, 2.7].
Pregnancy	Preferable to avoid as a precautionary measure due to limited data on use in pregnant women [1.1, 2.3].
Lactation/Breastfeeding	Not recommended; it is unknown if the substance is excreted in human milk, and a risk to the infant cannot be excluded [1.1, 2.3].

---

Condition-Specific Limitations

For an acute hemorrhoidal attack, Disolina use is strictly limited to short-term symptomatic treatment. The regulatory label stipulates that if symptoms persist, treatment must be re-evaluated [2.3]. Use is established for the adult population (18 years and older) [1.1].

Interactions with Other Medicines and Products

The official interaction profile for Disolina (Diosmin and Hesperidin) identifies specific substance categories and medicinal products that require regulatory caution upon co-administration.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Anticoagulant / Antiplatelet drugs, CYP450 3A4 / 2C9 / 2E1 substrates, and P-glycoprotein (P-gp) substrates
Specific interacting medicines (if explicitly listed)	Warfarin, Diclofenac, Fexofenadine, Carbamazepine, Chlorzoxazone, and certain herbal supplements that affect coagulation.
Mechanistic basis of interactions (only if stated in label)	Alteration of the drug efflux transporter P-glycoprotein (P-gp) and inhibition of specific CYP450 enzyme metabolic pathways.
Timing-based interaction rules (if applicable)	No mandatory administration timing separation rules are explicitly documented.
Interaction-related restrictions	Patients must inform their healthcare provider about all co-administered medicines, especially those that slow clotting or are known CYP/P-gp substrates.

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Interactions are primarily classified as Use with Caution or a requirement to Inform your doctor if co-administered. Some regulatory documents state that no clinically relevant drug interaction has been reported in post-marketing experience.

Resulting Interaction Structure

The regulatory documentation defines the product’s interaction structure through two primary classes: a pharmacodynamic risk of increased bleeding when combined with anticoagulants and antiplatelet drugs, and a pharmacokinetic risk of altered exposure for co-administered medicines. The altered exposure stems from the potential to inhibit the P-gp transporter and specific CYP450 enzymes. This structure formally establishes the need for regulatory caution when the medicine is co-administered with specific enzyme or transporter substrates like Diclofenac and Fexofenadine.

Disolina is a small molecule inhibitor that primarily targets the cyclooxygenase enzymes, COX-1 and COX-2. Its principal mechanism involves the competitive obstruction of the binding site for the endogenous substrate, arachidonic acid, within the active pocket of these enzymes. By this interaction, Disolina noncovalently reduces the enzymatic activity of both COX-1 and COX-2, with a mild preference toward COX-2 inhibition in some tissues.

This molecular inhibition results in a downstream reduction in the intracellular synthesis of prostanoids, which are derivatives of arachidonic acid. Specifically, the production of key mediators, including prostaglandin E2 (PGE2), prostacyclins, and thromboxanes, is attenuated. The subsequent intracellular consequences involve decreased levels of these signaling lipids, which function as autocoids and paracrine factors. At a system-level, the modulation of PGE2 synthesis alters the biochemical environment in various tissues, notably those associated with inflammatory and nociceptive signaling cascades, ultimately resulting in a systemic reduction of prostanoid-mediated physiological responses.

Disolina is administered through the oral route as a micronized film-coated tablet. It is commonly available in strengths of 500 mg and 1000 mg of the micronized purified flavonoid fraction. The tablets are typically taken at mealtimes.

Usage Patterns and Frequency

Usage patterns are based on the clinical context. For long-term management of chronic venous insufficiency, the standard regimen involves a total daily dose of 1000 mg. This dose is typically administered as one 1000 mg tablet once daily or two 500 mg tablets in divided doses.

In contrast, the use of Disolina for acute hemorrhoidal attacks follows a standardized, short-term, 7-day protocol. This regimen commences with an initial high daily dose that is reduced to a lower, tapered daily dose for the final 3 days. These doses are generally taken in divided intervals throughout the day.

Administration Details

The medicine is not recommended for individuals under the age of 18. The score line found on some tablets is solely intended to assist in swallowing and does not designate the tablet for division into equal doses.

Research Evidence / Overview of Studies for Disolina

Evidence for Use in Chronic Venous Disease (CVD)

Disolina was studied for the symptom management associated with Chronic Venous Disease (CVD), a condition where symptoms may vary in intensity, causing outcomes related to physical discomfort like leg heaviness and swelling. The main evidence comes from many Randomized Controlled Trials (RCTs), a common study design used in drug development, as well as Systematic Reviews and Meta-analyses that pool data from those trials. These studies were evaluated in adult populations experiencing varying degrees of CVD.

These trials focused on patient-reported outcomes describing perceived discomfort and changes in the symptoms that patients reported. Findings describe patterns observed in the studies where patients taking Disolina and reporting their experience. Research was used in studies examining symptom intensity or variability over observation periods lasting from two to six months. In addition to patient-reported data, research also examined objective measures, such as changes in leg circumference, which is used in trials assessing short-term or episodic symptom patterns, like swelling.

What Research Examined: Symptoms and Objective Measures

Studies were conducted during periods of increased symptom activity and evaluated in large groups of adult patients. Research examined how patient-reported outcomes describing perceived discomfort—such as leg heaviness, pain, and nocturnal cramps—evolved in the observed populations. Studies monitored physical changes, such as swelling, by measuring leg volume or circumference. This research provides insight into short-term changes but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Research on Advanced CVD Stages (Venous Ulcers)

The evidence landscape also includes studies specific to the more advanced stages of the disease, specifically focusing on patients with venous leg ulcers. In these settings, Disolina was evaluated in patients alongside standard care, such as compression bandaging. The research examined time to complete healing of venous leg ulcers and whether they returned later. This research contributes to the broader evidence landscape by looking at conditions marked by functional limitations and chronic changes.

Long-Term Studies and Follow-up Durations

The follow-up durations were limited for many of the core trials investigating symptom management and swelling, most often ranging from a few weeks up to six months. While these periods were used in research exploring short-term symptom changes, there is limited information for long-term outcomes regarding the progression of Chronic Venous Disease itself. Research exploring the persistence or consistency of findings over many years is still emerging. Consequently, research on long-term effects are not fully established because evidence beyond the intermediate follow-up periods of the core trials is limited.

Evidence in Special Populations

The research has primarily examined the effects of Disolina in the general adult population with Chronic Venous Disease. Data for certain groups, such as those who are elderly or those with specific co-existing medical conditions, remain insufficient because these populations were often not included in the core trials. The results apply only to the populations studied, and subgroup findings are uncertain. Comparative evidence is lacking for many specific patient groups.

What is Still Uncertain About Disolina

The evidence quality varies across studies; differences in methods and reporting was observed in some older studies. This may lead to mixed findings when results are combined in systematic reviews. Furthermore, research provides context but not individual predictions. While findings describe group patterns, they do not determine whether an individual will respond similarly. The research is ongoing to provide clearer insights into the most effective use over very long periods and in special populations.

Common questions about Disolina (FAQ)

Q: How is Disolina different from other medicines that treat the same condition?

Official information describes Disolina as a micronized purified flavonoid fraction (MPFF), which is a fixed-dose combination of the active bioflavonoids Diosmin and Hesperidin. This formulation is distinct from single-agent phlebotonic medicines. The micronization process is a specialized feature intended to enhance absorption and bioavailability of the ingredients.

---

Q: Is it normal to feel tired or dizzy when starting Disolina?

Dizziness and malaise (a general feeling of discomfort or tiredness) are included in the official safety profile. Regulatory documents classify these as Rare side effects, meaning they may occur in up to 1 in 1,000 people. Consultation with a healthcare provider is recommended if these effects persist.

---

Q: How will I know if Disolina is working for me?

The product is indicated for the relief of symptoms associated with compromised venous circulation. These symptoms typically include feelings of heavy legs, pain, and nocturnal cramps (restless leg syndrome). The medicine's activity is confirmed by improving venous tone and capillary resistance, which is intended to support a reduction of these discomforts.

---

Q: Is it true that Disolina has been studied for conditions other than its main use?

Yes, while the primary indications relate to chronic venous disease (CVD) and acute hemorrhoids, the evidence base includes studies that examined its use in treating more advanced stages of CVD. Specifically, the medicine has been studied for its role in the healing of venous leg ulcers when used alongside standard care like compression bandaging.

---

Q: Are there known long-term side effects that appear after years of use?

Research on the long-term use of Disolina has focused primarily on efficacy outcomes over periods up to six months. Regulatory documents acknowledge that due to the limited duration of core trials, long-term safety beyond this intermediate period is not fully established. Evidence concerning effects after many years of use is still emerging.

---

Q: Can Disolina be taken with daily vitamins or herbal supplements?

The official interaction profile identifies certain herbal supplements that may require caution. While no clinically relevant interaction has been confirmed for common daily vitamins, no specific interaction studies have been performed with all supplements. Official guidance recommends that patients inform their healthcare provider about all co-administered medicines, including vitamins and herbal products.

---

Q: What is the difference between a common and a serious side effect?

Regulatory bodies classify side effects based on how often they are expected to occur (frequency) and their clinical significance. Common side effects, such as gastrointestinal disturbances, affect up to 1 in 10 people. A Serious reaction, such as a severe hypersensitivity reaction like Angioedema (a form of severe localized swelling), is categorized by its clinical significance and potential to cause major health consequences, regardless of how rarely it occurs.

---

Q: Is there a maximum recommended duration for Disolina use?

The recommended duration of use is condition-specific according to official guidelines. For the treatment of acute hemorrhoidal attacks, use is strictly limited to a short-term, 7-day protocol. The regimen for chronic venous insufficiency is typically for long-term use.

---

Q: Does Disolina have a brand name equivalent?

Yes, the active ingredients, Diosmin and Hesperidin, are scientifically known as the micronized purified flavonoid fraction (MPFF). This combination is available under various registered brand names in different global regions, such as DAFLON.

---

Q: How quickly does Disolina start to show an effect?

The time required to observe a noticeable improvement in symptoms can vary among individuals. Studies and official information indicate that beneficial effects for vein-related issues are often observed within 2 to 3 weeks of beginning consistent daily use.

---

Q: Are there any foods or drinks I should avoid while taking Disolina?

No specific foods or drinks are required to be avoided while taking this medicine. The regulatory instructions regarding administration simply state that the tablets must be taken at mealtimes.

---

Q: Can I drink alcohol while I am on Disolina?

No clinically relevant interactions with alcohol have been officially reported based on post-marketing experience. Consultation with a healthcare provider is generally recommended for patients who intend to consume alcohol during the course of treatment.

---

Q: Can someone with kidney issues use Disolina?

Regulatory documents state that no specific dose adjustment studies have been performed for individuals with kidney issues. Due to this lack of data, consultation with a healthcare provider is recommended for those with underlying kidney conditions.

---

Q: Can someone with liver problems use Disolina?

Regulatory documents indicate that no specific dose adjustment studies have been performed for individuals with liver problems. Consultation with a healthcare provider is recommended for those with underlying liver conditions.

---

Q: Is Disolina a controlled substance?

Disolina is classified pharmacologically as a phlebotonic agent or venoactive drug. It is generally positioned as an over-the-counter (OTC) medicine in many regions and is not designated as a controlled substance.

---

Q: Are there any lifestyle changes that might improve the effectiveness of Disolina?

Official patient guidance states that treatment for venous circulation disorders is most effective when combined with a healthy lifestyle. This may include general recommendations like avoiding exposure to sun and heat, limiting periods of standing for too long, and managing excess weight.

---

Q: How does the mechanism of Disolina compare to older treatments for this condition?

Disolina is classified as a fixed-dose combination of bioflavonoids. Its mechanism of action centers on increasing venous parietal tone and improving both the microcirculation and lymphatic drainage.

---

Q: Will taking Disolina affect my ability to drive or operate machinery?

No specific regulatory warning is typically necessary regarding the ability to drive or use heavy machinery. However, regulatory information advises that if Rare side effects such as dizziness or headache occur, patients should exercise caution regarding driving or operating machinery.

---

Q: Can Disolina cause or worsen mood changes or depression?

No evidence suggests that the active ingredients have a direct effect on mood or mental health. If any unexpected changes in mood or mental well-being are experienced, consultation with a healthcare provider is recommended.

---

Q: Is there an official Medication Guide or Patient Information Leaflet for Disolina?

Yes, regulatory documentation requires that patient-facing information be made available. Documents such as a Patient Information Leaflet (PIL) or similar guidance are provided to ensure correct use and detail the safety profile and necessary cautions for patients.

---

Q: Can Disolina affect my fertility?

Non-clinical data, such as animal studies focusing on reproductive toxicity, do not indicate a special hazard regarding fertility. This type of research informs the general safety assessment of the product.

---

Q: What should be done if I experience a side effect that is not listed?

Regulatory bodies require the reporting of suspected side effects. Consultation with a doctor, pharmacist, or other healthcare provider is recommended for reporting any adverse effects, including those not listed in the official product information.

---

Q: Can Disolina be used by individuals who have diabetes?

Diabetes is not listed as a contraindication for using the medicine. However, consultation with a healthcare provider is recommended for individuals with diabetes or any other complex underlying medical condition.

---

Q: Will Disolina interact with birth control pills?

The medicine may interact with drug classes that are substrates of the CYP450 3A4 enzyme, which includes some hormonal contraceptives. While no specific studies have been performed, patients are advised to inform their healthcare provider about using oral contraceptives.

How to Store and Dispose of Disolina (Diosmin/Hesperidin)

Disolina must be stored strictly according to the conditions defined in the regulatory labeling to maintain product stability and safety.

Official Storage Requirements

Requirement	Details (As stated in regulatory documents)
Temperature Constraint	Store at a temperature not exceeding 30°C.
Environmental Protection	Protect the tablets from both light and moisture.
Container Rules	Keep the medicine in its original container, which must remain tightly closed.

Child Safety and Disposal

To prevent accidental access, Disolina must be kept out of the sight and reach of children at all times.

For disposal, the medicine must not be thrown away in wastewater or household trash. Instead, unused or expired tablets must be disposed of by following local regulations or by consulting a pharmacist for guidance on established medicine take-back programs.